Erasca ($ERAS) ERAS-0015 Data and Legal Risk Case

Attorneys review the case details to decide whether to proceed with a class action.

S.D. California

Court

3:26-cv-03481

Case number

01/14/2025

Class period Start

04/26/2026

Class period End

08/10/2026

Lead Plaintiff motion deadline

$ERAS investors filed a claim against Erasca for allegedly overstating ERAS-0015’s advantages while hiding risks tied to comparisons with Revolution Medicines’ RMC-6236.
After Erasca disclosed ERAS-0015 safety data and limits on comparisons to other drug candidates, $ERAS fell 48.3% on April 28, 2026.
$ERAS investors can join this case to be notified about potential recovery.
Case Details:

Between January 14, 2025 and April 26, 2026, Erasca told investors ERAS-0015 was a potential best-in-class pan-RAS molecular glue for RAS-mutant solid tumors. Executives emphasized ERAS-0015’s higher CYPA binding affinity, stronger preclinical potency, lower-dose activity, and promising pharmacokinetic profile compared with RMC-6236.

However, during this period, investors allege Erasca’s comparisons to RMC-6236 were improper and exposed the company to legal challenges. Erasca allegedly failed to disclose that its preclinical comparisons to RMC-6236 were allegedly misleading. ERAS-0015 faced patent and trade secret allegations from Revolution Medicines, and positive statements about ERAS-0015 lacked a reasonable basis because the comparisons were not based on head-to-head clinical trials.

Then, on April 27, 2026, the company revealed that Revolution Medicines alleged that ERAS-0015 infringed a patent, engaged in alleged trade secret misuse, and compared it to RMC-6236 using allegedly deceptive statements. 

$ERAS fell 10.9%, closing at $19.15. Additional revelations followed later that day, including preliminary Phase 1 data, one patient death, and disclosure that comparisons to RMC-6236 were based on limited cross-study analyses. 

By April 28, 2026, shares had dropped to $9.90, representing a total decline of 53.9% over the correction period.

Based on these events, $ERAS investors filed a claim against Erasca, alleging the company:
It overstated ERAS-0015’s advantages.
It failed to warn investors that its comparisons to RMC-6236 carried legal and scientific risks.
It prompted investors to reassess Erasca as legal claims and clinical limitations emerged.
Investors argue Erasca misled the market about ERAS-0015’s competitive profile and development risks, causing losses when the truth emerged.

Case Type

US Securities Class Action

Case Status

Attorney Investigation

Alleged Offence

Misleading Statements,

Fraud,

Failure to Disclose,

Omissions

Suspected Party

Directors,

Management

Security Type

Stocks

Trade Direction

Long

Shock Event Date

04/28/2026

Filing date

06/10/2026

Lead Plaintiff Deadline

08/10/2026

Trusted by industry leaders

Endorsed by top professionals who trust our innovative solutions to drive impactful results.